Connor, Clark & Lunn Investment Management (CC&L)
STIM icon

Connor, Clark & Lunn Investment Management (CC&L)’s Neuronetics STIM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,110
Closed -$67K – 1205
2021
Q4 		$67K Sell
15,110
-4,668
-24% -$22.9K ﹤0.01% 1042
2021
Q3 		$130K Buy
+19,778
New +$190K ﹤0.01% 969

Other funds holding STIM

CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s STIM Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Neuronetics (STIM) in Q1 2022, closing a stake of 15,110 shares — an estimated $67K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in STIM in Q3 2021 and held it in 2 quarters. The position peaked at $130K in Q3 2021. 83 funds tracked by Wall St. Rank hold STIM as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Neuronetics position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 15,110 Neuronetics shares in Q1 2022, an estimated $67K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Neuronetics in Q3 2021 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Neuronetics position peaked at $130K in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Neuronetics as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.